Drug Search Results
More Filters [+]

IGN-ES001

Alternative Names: ign-es001, ignes001, ign es001
Latest Update: 2018-08-07
Latest Update Note: Clinical Trial Update

Product Description

Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IgNova
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IGN-ES001

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IGN-ES001-CR01

N/A

Completed

Fibromyalgia|Chronic Pain|Myofascial Pain Syndromes

2017-11-30

Recent News Events

Date

Type

Title